NCT00892502

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Copenhagen University Hospital at Herlev · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.

Conditions

• Hematological Diseases
• Hematological Malignancies
• Blood Diseases
• Malignant Lymphoma
• Leukemia
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Bismuth tablets	1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
DRUG	Placebo tablets	1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy

Timeline

• Start date: 2009-05-01
• Primary completion: 2012-01-01
• Completion: 2013-02-01
• First posted: 2009-05-04
• Last updated: 2013-09-10

Locations

1 site across 1 country: Denmark